STICKLER SYNDROME

Stickler Syndrome — the most common inherited cause of retinal detachment, where prophylactic retinal treatment in childhood can prevent the blindness that occurs without it.

Whole genome sequencing evaluates all Stickler syndrome genes — COL2A1, COL11A1, COL11A2, COL9A1, COL9A2, COL9A3 — distinguishing the high-retinal-risk type 1 from low-retinal-risk type 2, which determines the intensity of ophthalmological surveillance.

CLIA CertifiedCAP AccreditedISO 15189 Medical LabACMG ClassifiedHIPAA & GDPR100,000+ Genomes Sequenced

About this condition

Stickler Syndrome

Stickler syndrome is the most common inherited connective tissue disorder, affecting approximately 1 in 7,500-9,000 births. It is caused by pathogenic variants in genes encoding collagen types II, IX, and XI — structural components of vitreous humor, cartilage, and inner ear. Six types are recognized based on the causative gene: type 1 (COL2A1, most common, ~75%), type 2 (COL11A1, ~10-15%), type 3 (COL11A2, non-ocular), type 4 (COL9A1), type 5 (COL9A2), and type 6 (COL9A3). Types 1 and 2 are autosomal dominant with variable expressivity; types 4-6 are autosomal recessive.

The cardinal features are ocular (myopia, vitreous anomalies, retinal detachment, cataracts), skeletal (Pierre Robin sequence, midface hypoplasia, micrognathia, joint hypermobility, early-onset osteoarthritis, spondyloepiphyseal abnormalities), and auditory (sensorineural and/or conductive hearing loss). Retinal detachment is the most vision-threatening complication — it occurs in approximately 60-70% of untreated type 1 patients (COL2A1 variants with membranous vitreous anomaly) but only ~5-10% of type 2 patients (COL11A1 variants with beaded vitreous anomaly). This dramatic difference in retinal detachment risk by genotype directly determines the ophthalmological surveillance intensity.

Prophylactic retinal treatment — cryotherapy or laser retinopexy applied to the peripheral retina in childhood — dramatically reduces retinal detachment risk in type 1 Stickler syndrome from ~60-70% to approximately 5-10%. The Cambridge prophylaxis study demonstrated that this simple intervention preserves sight in the majority of patients who would otherwise develop blindness from retinal detachment. However, prophylactic treatment is most beneficial in type 1 (COL2A1) patients; type 2 (COL11A1) patients have lower baseline risk and may not require prophylaxis. Molecular genotyping is therefore essential for determining the appropriate retinal management strategy.

Pierre Robin sequence (micrognathia, glossoptosis, cleft palate) in a neonate is frequently the first presentation of Stickler syndrome — all infants with Pierre Robin should have ophthalmological assessment and Stickler genetic testing.

Gene locus
COL2A1 (12q13.11), COL11A1 (1p21.1), COL11A2 (6p21.32), COL9A1/A2/A3

COL2A1 (type 1) vs. COL11A1 (type 2) determines retinal detachment risk — 60-70% vs. 5-10%. This single genotype distinction determines whether prophylactic retinal treatment is indicated.

Prophylactic retinal cryotherapy prevents blindness — but only if type 1 Stickler is identified before detachment occurs

The Cambridge prophylaxis protocol reduces retinal detachment in type 1 Stickler syndrome from ~65% to ~6% — one of the most effective preventive interventions in ophthalmology. However, it must be performed before the first detachment occurs, ideally in childhood. This requires early molecular diagnosis to identify type 1 (COL2A1) patients and implement prophylaxis before the detachment age window. Without molecular testing, Stickler patients may receive standard myopia management without the specialized retinal surveillance and prophylaxis that prevents blindness.

Every child with Pierre Robin sequence should be tested for Stickler syndrome — it is the most common underlying cause

Pierre Robin sequence (PRS) — micrognathia, glossoptosis (posterior tongue displacement), cleft palate — occurs in approximately 30-40% of Stickler syndrome type 1 patients. Conversely, Stickler syndrome is the most common identifiable cause of PRS. Any neonate with PRS should have comprehensive Stickler gene testing and immediate ophthalmological assessment. Without molecular testing, PRS is managed as an isolated malformation sequence — and the retinal detachment risk, hearing loss, and joint complications of underlying Stickler syndrome go unmonitored until they present clinically.

Others in Rare Diseases

Browse all conditions →

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks

Get my Genome Test